Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities - 05/10/20
Doi : 10.1016/j.jaci.2020.07.008
Zita-Rose Manjaly Thomas, PhD a, b, Anne Leuppi-Taegtmeyer, MD, PhD c, d, ∗, Dagmar Jamiolkowski, MD b, e, ∗, Esther Steveling-Klein, MD a, b, Felicitas Bellutti-Enders, MD b, f, Kathrin Scherer Hofmeier, MD a, b, ‡, Karin Hartmann, MD a, b, ⁎, ‡ 
a Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland
b Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland
c Regional Pharmacovigilance Centre, Department of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland
d Department of Pharmaceutical Sciences, University Hospital Basel, Basel, Switzerland
e Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland
f Allergy Unit, University Children’s Hospital Basel, Basel, Switzerland
∗Corresponding author: Karin Hartmann, MD, Division of Allergy, Department of Dermatology, University of Basel, Petersgraben 4, 4031 Basel, Switzerland.Division of AllergyDepartment of DermatologyUniversity of BaselPetersgraben 4Basel4031Switzerland
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Key words : Acute respiratory syndrome, adverse drug reactions, coronavirus, COVID-19, drug allergy, drug hypersensitivity, remdesivir, SARS-CoV-2
Il testo completo di questo articolo è disponibile in PDF.
Mappa
| Disclosure of potential conflict of interest: Z.-R. M. Thomas has received funding for congress attendance from Sanofi. D. Jamiolkowski has received funding for congress attendance from Stallergenes. E. Steveling-Klein has a transfer of value agreement with Bencard and has received funding for congress attendance from ALK. K. S. Hofmeier has received funding from Allergopharma, Sanofi-Aventis, Shire, and Novartis. K. Hartmann has received research funding from Euroimmun and consultancy or lecture fees from Allergopharma, ALK-Abelló, Blueprint, Deciphera, Menarini, Novartis, and Takeda. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2020
American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 146 - N° 4
P. 786-789 - Ottobre 2020 Ritorno al numero
Articolo precedente
- Pumping mast cells out of allergic inflammation—are proton pump inhibitors taking center stage?
- Netali Ben Baruch-Morgenstern, Mark Rochman, Marc E. Rothenberg
- Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study
- Jee Myung Yang, Hyun Yong Koh, Sung Yong Moon, In Kyung Yoo, Eun Kyo Ha, Seulgi You, So Young Kim, Dong Keon Yon, Seung Won Lee
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.